Form 4: Amylyx Pharmaceuticals Co-CEO Joshua Cohen Sells Shares to Cover Tax Obligations

Joshua Cohen, Co-CEO of Amylyx Pharmaceuticals, sold 4,135 shares of common stock on March 5, 2024, to cover tax withholding obligations related to vesting restricted stock units.

Summary

• On March 5, 2024, Joshua Cohen, Co-CEO of Amylyx Pharmaceuticals, sold 4,135 shares of the company's common stock.
• The sale was executed to cover tax withholding obligations associated with the vesting of restricted stock units.
• The shares were sold at a weighted average price of $18.7279, with individual transactions ranging from $18.62 to $18.82.
• Following the transaction, Cohen directly owns 3,023,002 shares of Amylyx Pharmaceuticals.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction (stock sale for tax obligations) and doesn't inherently indicate positive or negative sentiment regarding the company's prospects.

Industry Context

Form 4 filings are a routine part of the US stock market, providing transparency into the transactions of company insiders. This sale appears to be related to tax obligations, which is a common reason for such transactions.

Stakeholder Impact

• The sale of shares by an executive could be perceived negatively by some shareholders, although the stated reason (tax obligations) mitigates this concern.

Key Dates